← Back to Search

Other

Terameprocol for Brain Tumor

Phase 1
Waitlist Available
Led By Manmeet Ahluwalia, MD
Research Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
- 6 weeks from a nitrosourea chemotherapy
- 3 weeks from a non-nitrosourea chemotherapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 - day28 (first cycle)
Awards & highlights

Study Summary

This trial is testing the side effects and best dosage of a drug called terameprocol in treating patients with high-grade glioma that has returned.

Eligible Conditions
  • Brain Tumor

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have received nitrosourea chemotherapy within the past 6 weeks.
Select...
You have received a type of chemotherapy other than nitrosourea within the past 3 weeks.
Select...
The surgeon should be able to remove a certain amount of tumor during surgery without causing harm to the brain.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 - day28 (first cycle)
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 - day28 (first cycle) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in terameprocol tumor to plasma concentration ratio (Part 2)
Maximum tolerated days of terameprocol dosing that can safely be administered on a continuous basis (Part 3)
Maximum tolerated dose of terameprocol (Part 1)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (terameprocol)Experimental Treatment2 Interventions
Patients receive terameprocol PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Pharmacological Study
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Terameprocol
2018
Completed Phase 1
~20

Find a Location

Who is running the clinical trial?

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor
554 Previous Clinical Trials
32,891 Total Patients Enrolled
Erimos PharmaceuticalsIndustry Sponsor
5 Previous Clinical Trials
84 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,606 Previous Clinical Trials
40,913,464 Total Patients Enrolled

Media Library

Terameprocol (Other) Clinical Trial Eligibility Overview. Trial Name: NCT02575794 — Phase 1
Brain Tumor Research Study Groups: Treatment (terameprocol)
Brain Tumor Clinical Trial 2023: Terameprocol Highlights & Side Effects. Trial Name: NCT02575794 — Phase 1
Terameprocol (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02575794 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many facilities are implementing this experiment?

"UAB Comprehensive Cancer Center in Birmingham, Alabama; Abrams Cancer Center of the University of Pennsylvania in Philadelphia, Pennsylvania; and Josephine Ford Cancer Center at Henry Ford Hospital in Detroit, Michigan are just some of the medical centres actively recruiting for this clinical trial. An additional 8 sites have also been identified as potential enrolment locations."

Answered by AI

Have any other investigations explored the use of Terameprocol?

"At present, there is one ongoing clinical trial researching the effects of Terameprocol. It has yet to reach Phase 3 and is currently running out of 10 different medical centres, with a notable presence in New york City."

Answered by AI

To what extent are individuals partaking in this experiment?

"This clinical trial is not currently accepting any more candidates. Initially posted on May 3rd 2018, the study was last modified on August 5th 20202. Although this research is closed to new patients, there are 356 trials recruiting glioma participants and one investigation looking for Terameprocol volunteers presently in progress."

Answered by AI

Has Terameprocol been accepted by the FDA for use?

"Given its status as a Phase 1 trial, which involves limited data about safety and efficacy, our team at Power assessed Terameprocol's safety with an estimated score of 1."

Answered by AI

Is this endeavor the inaugural attempt at a similar experiment?

"Since its initial clinical trial in 2018, sponsored by Erimos Pharmaceuticals and involving 20 patients, Terameprocol has gone through the Phase 1 drug approval stage. Currently, there is one ongoing research led by Erimos Pharmaceuticals that involves this medication."

Answered by AI

Are there any open slots available for this medical research project?

"This trial is temporarily closed for recruitment, with the original posting date being May 3rd 2018 and its most recent update on August 5th 2022. However, there are presently 356 clinical trials enrolling patients suffering from glioma and one active medical study recruiting participants to test Terameprocol."

Answered by AI
~3 spots leftby Mar 2025